Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).
Authors
Yuhong Dai
Tongji Hospital, Wuhan, China
Yuhong Dai , Xiongjie Yu , Huiting Xu , Liang Zhuang , Mingsheng Zhang , Yanmei Zou , Qiang Fu , Hong Qiu , Xianglin Yuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03801668
DOI
10.1200/JCO.2022.40.4_suppl.282
Abstract #
282
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of autologous lymphocytes combined with chemotherapy as the first-line treatment of advanced gastric cancer.
First Author: Xiaoting Ma
Poster
2018 Gastrointestinal Cancers Symposium
A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-cubed (C3) study.
First Author: Hitoshi Ojima
Poster
2016 ASCO Annual Meeting
Phase III trial of s-1 plus oxaliplatin (SOX) vs s-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOPP study.
First Author: Min-Hee Ryu
Poster
2013 Gastrointestinal Cancers Symposium
Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
First Author: Katsuhiko Higuchi